How TripleAiM1 leads to personalised treatment patient pathways for mHSPC patients
About the collaboration
The research project tripleAiM1 contributes to the development of personalised patient pathways for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This is a collaborative research project between RadboudUMC, CWZ and fourteen other Dutch hospitals, Janssen and LOGEX.
The challenge
For patients with mHSPC, the treatment landscape is getting more complicated each day. A large number of treatment options available increases survival, but also increases the complexity of personalised patient pathways. Identifying the optimal treatment pathway for each patient is impossible for healthcare providers without Real World Data. Especially because each new treatment option has unknown clinical efficacy, impact on quality of life (QoL) and effect on healthcare consumption. Turning Real World Data from several hospitals into Real World Evidence will allow healthcare providers to personalise treatment pathways of their patients.
Janssen reached out to LOGEX to link Real World Data from several hospitals to predict preferable outcomes of different treatment options tailored to the preferences and needs of a patient.
“LOGEX collects individual utility and expenditure data related to DBCs from hospital records. This infrastructure has presently included over 300 of the total 450 de novo mHSPC patients to answer its initial objective, and has proven ability to rapidly recruit de novo mHSPC patients. TripleAIM1 has provided a wealth of data on de novo mHSPC patients, with its objective in unravelling variability in use of diagnostic tools and shifting treatment patterns in the Netherlands.”
Niven Mehra, PI and doctor at RadboudUMC
“Through this project we managed to converts sets of complex hospital data into clean analytical views, capable of generating real impact for the physicians and the patients. It is extremely rewarding to see how data is turned into real actionable change.”
Nicole Kerklaan, TripleAim1 Project Manager
The solution
LOGEX is specialised in structuring Real Word Data and generating Real World Evidence, resulting in actionable insights. For the TripleAiM1 study, LOGEX collected data about clinical and patient-reported outcomes. For instance, data coming from questionnaires related to the patient and tumour characteristics. The development of a patient dashboard was possible after gathering this information. This method helped to complete the mission to personalise patient pathways.
TripleAim1 includes clinical trial outcomes and QoL
The TripleAiM1 is a one-of-a-kind study because it includes both Clinical and Patient Related Outcome Measures (CROMs & PROMs).
The patient pathway can be adjusted by the healthcare provider based on QoL scores of the patients over time. The optimal treatment strategy for a patient can be optimised by performing a comparison with other patients who are receiving the same type of treatment.
Data sharing & care optimisation
Sharing retrospective and prospective data about mHSPC patients and treatment pathways among different hospitals allows healthcare professionals to benchmark new treatment options. We can only find the optimal therapy flow by measuring CROMs and PROMs. Optimising care by implementing the best practices ultimately leads to care optimization, benefiting the healthcare professional and the patient.
Patient-centred care and patient engagement
By creating a patient dashboard that includes CROMs and PROMs, patient preferences are included as an important factor for determining the direction of the patient pathway. This means that the patient and the healthcare provider are both aware of treatment possibilities and preferable outcomes.
Shared decision-making between healthcare providers and patients requires a cultural shift from a doctor-centred to a patient-centred approach. In this new culture, the assumption that the doctor knows best no longer dominates the relationship between patients and doctors. Shared decision-making is the only way to fully practice informed decision-making. This results in patient engagement and confidence in treatment since patients have more ownership of their pathway.
Impact
TripleAiM1 contributes to the future of personalised healthcare. Tailored treatment trajectories are possible for mHSPC patients because of studies like this. The future of personalised healthcare for patients is getting closer. Setting-up similar studies for other diseases might lead to personalised healthcare for multiple high-impact therapeutic areas. The benefit is better patient engagement, treatment compliance and shorter consultations. This reduces healthcare costs and improves its quality.
